Moderna Net Income 2017-2021 | MRNA

Moderna annual/quarterly net income history and growth rate from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Moderna net income for the quarter ending September 30, 2021 was $3.333B, a 1530.47% decline year-over-year.
  • Moderna net income for the twelve months ending September 30, 2021 was $7.061B, a 1282.16% decline year-over-year.
  • Moderna annual net income for 2020 was $-0.747B, a 45.34% increase from 2019.
  • Moderna annual net income for 2019 was $-0.514B, a 27.91% increase from 2018.
  • Moderna annual net income for 2018 was $-0.402B, a 48.92% increase from 2017.
Moderna Annual Net Income
(Millions of US $)
2020 $-747
2019 $-514
2018 $-402
2017 $-270
2016 $-230
Moderna Quarterly Net Income
(Millions of US $)
2021-09-30 $3,333
2021-06-30 $2,780
2021-03-31 $1,221
2020-12-31 $-273
2020-09-30 $-233
2020-06-30 $-117
2020-03-31 $-124
2019-12-31 $-123
2019-09-30 $-123
2019-06-30 $-135
2019-03-31 $-133
2018-12-31 $-141
2018-09-30 $-88
2018-06-30 $-94
2018-03-31 $-76
2017-12-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $83.008B $0.803B
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69